Lipid nanoparticle delivery of unmodified mRNAs encoding multiple monoclonal antibodies targeting poxviruses in rabbits.
MT: Delivery strategies
RNA
lipid nanoparticle
monoclonal antibodies
neutralizing antibody
nucleic acid
poxvirus
rabbits
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
14 Jun 2022
14 Jun 2022
Historique:
received:
15
11
2021
accepted:
07
05
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Poxviruses are a large and complex family of viruses with members such as monkeypox virus and variola virus. The possibility of an outbreak of monkeypox virus (or a related poxvirus) or the misuse of variola virus justifies the development of countermeasures. Furthermore, poxviruses can be a useful surrogate for developing technology involving antibody therapies. In our experiments, we explored the feasibility of utilizing unmodified mRNA that encodes three previously described monoclonal antibodies, c8A, c6C, and c7D11, as countermeasures to smallpox in a relatively large (>3 kg) laboratory animal (rabbits). We confirmed
Identifiants
pubmed: 35664703
doi: 10.1016/j.omtn.2022.05.025
pii: S2162-2531(22)00138-X
pmc: PMC9149018
doi:
Types de publication
Journal Article
Langues
eng
Pagination
847-858Subventions
Organisme : NCBDD CDC HHS
ID : U01 DD001144
Pays : United States
Déclaration de conflit d'intérêts
P.B. and C.T.-S. are employed by CureVac, a company that has licensing rights related to the mRNA utilized in these studies. J.W.H. is an inventor on a patent related to mAb c7D11 and antibody therapies generated using L1, A33, and B5 as antigens. These interests do not alter the authors’ adherence to policies on sharing data and materials.
Références
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1882-7
pubmed: 16436502
Prog Med Virol. 1973;16:86-108
pubmed: 4356899
EMBO Mol Med. 2017 Oct;9(10):1434-1447
pubmed: 28794134
Virol J. 2011 Sep 20;8:441
pubmed: 21933385
Sci Immunol. 2019 May 17;4(35):
pubmed: 31101672
Adv Exp Med Biol. 2015;848:149-67
pubmed: 25757620
Virology. 1995 Aug 1;211(1):53-63
pubmed: 7645236
Sci Rep. 2020 May 29;10(1):8764
pubmed: 32472093
Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):E1941-E1950
pubmed: 28202722
Immunity. 2005 Aug;23(2):165-75
pubmed: 16111635
PLoS One. 2015 Jul 06;10(7):e0131742
pubmed: 26147658
Expert Rev Vaccines. 2011 Jul;10(7):1021-35
pubmed: 21806397
J Virol. 2011 Sep;85(17):9147-58
pubmed: 21715493
Curr Gene Ther. 2014;14(3):200-10
pubmed: 24867065
Neuro Oncol. 2017 Mar 1;19(3):372-382
pubmed: 27765835
MAbs. 2013 Sep-Oct;5(5):810-6
pubmed: 23924803
Pediatrics. 1960 Aug;26:176-89
pubmed: 14408455
PLoS One. 2012;7(11):e48706
pubmed: 23133652
J Virol. 2007 Sep;81(17):8989-95
pubmed: 17581986
Sci Rep. 2015 Jul 29;5:12616
pubmed: 26220099
Lancet. 2017 Sep 23;390(10101):1511-1520
pubmed: 28754494
Immunity. 2021 Dec 14;54(12):2877-2892.e7
pubmed: 34852217
J Control Release. 2015 Nov 10;217:345-51
pubmed: 26264835
Virology. 2020 May;544:42-54
pubmed: 32174513
PLoS One. 2012;7(7):e42353
pubmed: 22860117
Proc R Soc Med. 1969 Mar 3;62(3):295-7
pubmed: 4307230
Mol Ther. 2015 Sep;23(9):1456-64
pubmed: 26050989
Nature. 2017 Mar 9;543(7644):248-251
pubmed: 28151488
J Virol. 2005 Nov;79(21):13454-62
pubmed: 16227266
PLoS Negl Trop Dis. 2018 Jun 21;12(6):e0006581
pubmed: 29927927
Lancet. 1973 Mar 24;1(7804):656-9
pubmed: 4121857
Am J Epidemiol. 1971 Dec;94(6):612-20
pubmed: 4332354
Viruses. 2010 Oct;2(10):2381-2403
pubmed: 21197387
Hum Vaccin Immunother. 2013 Oct;9(10):2253-62
pubmed: 24045230
Nat Commun. 2017 Mar 02;8:14630
pubmed: 28251988
J Infect Dis. 2016 Aug 1;214(3):369-78
pubmed: 27001960
Clin Pharmacol Ther. 2008 Nov;84(5):548-58
pubmed: 18784655